A Phase 1 interventional study of BMS-986278 in Hepatic Impairment and Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Liver Diseases by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Liver Diseases · Bristol-Myers Squibb.
Among the 11 studies in Liver Diseases by Bristol-Myers Squibb, this one is one of 3 that started in 2024, is one of 7 in phase 1, and was the 10th registered.
824 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →None of the 11 studies in Liver Diseases by Bristol-Myers Squibb is open now. The open studies under Liver Diseases, anywhere →
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 52 across 522 interventional studies indexed under Liver Diseases.
Median enrollment 32 across the 9 interventional studies, 595 across the 2 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Liver Diseases by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Participants:
Mild, Moderate, or Severe Hepatic Impairment Participants:
Matched Healthy Participants:
Exclusion Criteria:
All Participants:
Mild, Moderate, or Severe Hepatic Impairment Participants:
Matched Healthy Participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278
Drug: BMS-986278
Drug: BMS-986278
Drug: BMS-986278
Specified dose on specified days
Maximum observed concentration (Cmax)
Time frame: Up to day 9
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Time frame: Up to day 9
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time frame: Up to day 9
Incidence of adverse events (AEs)
Time frame: Up to 62 days
Incidence of serious adverse events (SAEs)
Time frame: Up to 62 days
Number of participants with physical examination abnormalities
Time frame: Up to 62 days
Number of participants with vital sign abnormalities
Time frame: Up to 62 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 62 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 62 days
Time of maximum observed concentration (Tmax)
Time frame: Up to day 9
Terminal elimination half-life (T-HALF)
Time frame: Up to day 9
Apparent body clearance (CLT/F)
Time frame: Up to day 9
Maximum observed plasma concentration of unbound drug (Cmax_u)
Time frame: Up to day 9
Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration of unbound drug [AUC(0-T)_u]
Time frame: Up to day 9
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time of unbound drug [AUC(INF)_u]
Time frame: Up to day 9
Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html
Ran from Jun 2024 to primary completion in Dec 2024, 6 months.
Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.
Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Admilparant